CD274 and neoplasm: Treatment is performed by administration of monoclonal antibodies which block the coinhibitory surface receptors or their ligands: programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) on immune cells as well as programmed cell death ligand 1 (PD-L1) on immune cells and tumor cells.